Conditions: Prostate Cancer
Keywords: Advanced Prostate Cancer Prostate Cancer Trabectedin ET 743 Yondelis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 50
Healthy volunteers: no

Brief summary:
The main purpose of this study is to find out what effects (good or bad) trabectedin (ET743) has on men with advanced prostate carcinoma.

Detailed description:
* Treatment with trabectedin will be given once a week for three consecutive weeks with one week of no treatment. This four week period constitutes one cycle.
* Trabectedin is given as an infusion through a central venous catheter and is administered over 3 hours.
* On day 1 of each cycle a history, physical exam and blood tests will be performed and trabectedin will be administered.
* On day 8 and day 15 of each cycle blood work will be performed and trabectedin will be administered.
* Patients will continue to receive trabectedin as long as there is no disease progression or unacceptable side effects.
* Scans (CT, MRI or bone) or x-rays may be done while the patient is on the trial at the discretion of the physician.

Arms:
arm 1: ET-743

Interventions: intervention 1: ET 743
Intervention descriptions: intervention 1: ET-743 administered IV by 24-hr infusion every 3 weeks

Protocol document: